Effects of ursolic acid on glucose metabolism, the polyol pathway and dyslipidemia in non-obese type 2 diabetic mice

Indian Journal of Experimental Biology

Volumn 52, Issue 7, 2014, Pages 683-691

  Lee, Jin ^a   Lee, Hae In ^a   Seo, Kown Il ^a   Cho, Hyun Wook ^a   Kim, Myung Joo ^b   Park, Eun Mi ^b   Lee, Mi Kyung ^a  

^a Sunchon National University   (South Korea)

^b Suseong College   (South Korea)

Author keywords

Dyslipidemia; Kidney; Liver; Polypol pathway; Ursolic acid

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 2; GLYCOGEN; MESSENGER RNA; POLYMER; POLYOL; SLC2A2 PROTEIN, MOUSE; TRITERPENE; URSOLIC ACID;

ANIMAL; ARTICLE; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HYPERGLYCEMIA; INSTITUTE FOR CANCER RESEARCH MOUSE; KIDNEY DISEASE; MALE; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONOBESE DIABETIC MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLUCOKINASE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 2; GLUCOSE-6-PHOSPHATASE; GLYCOGEN; HYPERGLYCEMIA; KIDNEY DISEASES; MALE; MICE; MICE, INBRED ICR; MICE, INBRED NOD; POLYMERS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRITERPENES;

EID: 84903790134     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Chan J C, Malik V, Jia W, Kadowaki T, Yajnik C S, Yoon K H & Hu F B, Diabetes in Asia: Epidemiology, risk factors, and pathophysiology, JAMA, 301 (2009) 2129.
2. Yoon K H, Lee J H, Kim J W, Cho J H, Choi Y H, Ko S H, Zimmet P & Son H Y, Epidemic obesity and type 2 diabetes in Asia, Lancet, 368 (2006) 1681.
3. Montanya E, Nacher V, Biarnes M & Soler J, Linear correlation between beta-cell mass and body weight throughout the lifespan in Lewis rats: Role of beta-cell hyperplasia and hypertrophy, Diabetes, 49 (2000) 1341.
4. Vaag A & Lund S S, Non-obese patients with type 2 diabetes and prediabetic subjects: Distinct phenotypes requiring special diabetes treatment and (or) prevention, Appl Physiol Nutr Metab, 32 (2007) 912.
5. Lear S A, Humphries K H, Kohli S, Chockalingam A, Frohlich J J & Birmingham C L, Visceral adipose tissue accumulation differs according to ethnic background: Results of the Multicultural Community Health Assessment Trial (M-CHAT), Am J Clin Nutr, 86 (2007) 353.
6. Cheung B M, Wat N M, Man Y B, Tam S, Thomas G N, Leung G M, Cheng C H, Woo J, Janus E D, Lau C P, Lam T H & Lam K S, Development of diabetes in Chinese with the metabolic syndrome: A 6-year prospective study, Diabetes Care, 30 (2007) 1430.
7. Thomas G N, Schooling C M, McGhee S M, Ho S Y, Cheung B M, Wat N M, Janus E D, Lam K S, Lam T H & Hong Kong cardiovascular risk factor prevalence study steering committee, Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study, Clin Endocrinol (Oxf), 66 (2007):666.
8. Yin M C & Chan K C, Nonenzymatic antioxidative and antiglycative effects of oleanolic acid and ursolic acid, J Agric Food Chem, 55 (2007) 7177.
9. Tian Z, Lin G, Zheng R X, Huang F, Yang M S & Xiao P G, Anti-hepatoma activity and mechanism of ursolic acid and its derivatives isolated from Aralia decaisneana, World J Gastroenterol, 12 (2006) 874.
10. Kwon S H, Park H Y, Kim J Y, Jeong I Y, Lee M K & Seo K I, Apoptotic action of ursolic acid isolated from Corni fructus in RC-58T/h/SA#4 primary human prostate cancer cells, Bioorg Med Chem Lett, 20 (2010) 6435.
11. Jung S H, Ha Y J, Shim E K, Choi S Y, Jin J L, Yun-Choi H S & Lee J R, Insulin-mimetic and insulin-sensitizing activities of a pentacyclic triterpenoid insulin receptor activator, Biochem J, 403 (2007) 243.
12. Jang S M, Yee S T, Choi J, Choi M S, Do G M, Jeon S M, Yeo J, Kim M J, Seo K I & Lee M K, Ursolic acid enhances the cellular immune system and pancreatic beta-cell function in streptozotocin-induced diabetic mice fed a high-fat diet, Int Immunopharmacol, 9 (2009) 113.
13. Lee J, Yee S T, Kim J J, Choi M S, Kwon E Y, Seo K I & Lee M K, Ursolic acid ameliorates thymic atrophy and hyperglycemia in streptozotocin-nicotinamide-induced diabetic mice, Chem Biol Interact, 188 (2010) 635.
14. Nakamura T, Terajima T, Ogata T, Ueno K, Hashimoto N, Ono K & Yano S, Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide, Biol Pharm Bull, 29 (2006) 1167.
15. American Institute of Nurtition, Report of the American Institute of Nurtition ad hoc committee on standards for nutritional studies, J Nutr, 107 (1977) 1340.
16. Glueck C J, Aregawi D, Winiarska M, Agloria M, Luo G, Sieve L & Wang P, Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome, J Pediatr Endocrinol Metab, 19 (2006) 831.
17. Suwa M, Egashira T, Nakano H, Sasaki H & Kumagai S, Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo, J Appl Physiol, 101 (2006) 1685.
18. Friedewald W T, Levy R I & Fredrickson D S, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18 (1972) 499.
19. Jang S M, Kim M J, Choi M S, Kwon E Y & Lee M K, Inhibitory effects of ursolic acid on hepatic polyol pathway and glucose production in streptozotocin-induced diabetic mice, Metabolism, 59 (2010) 512.
20. Schmittgen T D & Livak K J, Analyzing real-time PCR data by the comparative C(T) method, Nat Protoc, 3 (2008) 1101.
21. Kim M Y, Jo S H, Park J M, Kim T H, Im S S & Ahn Y H, Adenovirus-mediated overexpression of Tcfe3 ameliorates hyperglycaemia in a mouse model of diabetes by upregulating glucokinase in the liver, Diabetologia, 56 (2013) 635.
22. Girard J, Ferre P & Foufelle F, Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes, Annu Rev Nutr, 17 (1997) 325.
23. Postic C, Shiota M & Magnuson M A, Cell-specific roles of glucokinase in glucose homeostasis, Recent Prog Horm Res, 56 (2001) 195.
24. Grimsby J, Sarabu R, Corbett W L, Haynes N E, Bizzarro F T, Coffey J W, Guertin K R, Hilliard D W, Kester R F & Mahaney P E, Marcus L, Qi L, Spence C L, Tengi J, Magnuson M A, Chu C A, Dvorozniak M T, Matschinsky F M & Grippo J F, Allosteric activators of glucokinase: potential role in diabetes therapy, Science, 301 (2003) 370.
25. Pfefferkorn J A, Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes, Expert Opin Drug Discov, 8 (2013) 319.
26. Guo T, Mao Y, Li H, Wang X, Xu W, Song R, Jia J, Lei Z, Irwin D M, Niu G & Tan H, Characterization of the gene expression profile of heterozygous liver-specific glucokinase knockout mice at a young age, Biomed Pharmacother, 66 (2012) 587.
27. Xiao B, Sanders M J, Underwood E, Heath R, Mayer F V, Carmena D, Jing C, Walker PA, Eccleston J F, Haire L F, Saiu P, Howell S A, Aasland R, Martin S R, Carling D & Gamblin S J, Structure of mammalian AMPK and its regulation by ADP, Nature, 472 (2011) 230.
28. Wang Z H, Hsu C C, Huang C N & Yin M C, Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice, Eur J Pharmacol, 628 (2010) 255.
29. Rao A R, Veeresham C & Asres K, In vitro and in vivo inhibitory activities of four Indian medicinal plant extracts and their major components on rat aldose reductase and generation of advanced glycation endproducts, Phytother Res, 27 (2013) 753.
30. Ahmed N, Advanced glycation endproducts--role in pathology of diabetic complications, Diabetes Res Clin Pract, 67 (2005) 3.
31. Peyroux J & Sternberg M, Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes, Pathol Biol (Paris), 54 (2006) 405.
32. Chung S S & Chung S K, Aldose reductase in diabetic microvascular complications, Curr Drug Targets, 6 (2005) 475.
33. Ghule A E, Jadhav S S & Bodhankar S L, Trigonelline ameliorates diabetic hypertensive nephropathy by suppression of oxidative stress in kidney and reduction in renal cell apoptosis and fibrosis in streptozotocin induced neonatal diabetic (nSTZ) rats, Int Immunopharmacol, 14 (2012) 740.
34. Zhou Y, Li JS, Zhang X, Wu Y J, Huang K & Zheng L, Ursolic acid inhibits early lesions of diabetic nephropathy, Int J Mol Med, 26 (2010) 565.
35. Inzucchi S E, Oral antihyperglycemic therapy for type 2 diabetes: Scientific review, JAMA, 287 (2002) 360.
36. Lund S S, Tarnow L, Stehouwer C D, Schalkwijk C G, Teerlink T, Gram J, Winther K, Frandsen M, Smidt U M, Pedersen O, Parving H H & Vaag A A, Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes, Eur J Endocrinol, 158 (2008) 631.
37. Barter PJ, The causes and consequences of low levels of high density lipoproteins in patients with diabetes, Diabetes Metab J, 35 (2011) 101.
38. Tirosh A, Rudich A, Shochat T, Tekes-Manova D, Israeli E, Henkin Y, Kochba I & Shai I, Changes in triglyceride levels and risk for coronary heart disease in young men, Ann Intern Med, 147 (2007) 377.
39. Patel A, Barzi F, Jamrozik K, Lam T H, Ueshima H, Whitlock G, Woodward M & Asia Pacific Cohort Studies Collaboration, Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region, Circulation, 110 (2004) 2678.
40. Krentz A J, Lipoprotein abnormalities and their consequences for patients with type 2 diabetes, Diabetes Obes Metab 5 Suppl, 1 (2003) S19.
41. Shirwaikar A, Rajendran K, Dinesh Kumar C & Bodla R, Antidiabetic activity of aqueous leaf extract of Annona squamosa in streptozotocin-nicotinamide type 2 diabetic rats, J Ethnopharmacol, 91 (2004) 171.
42. Kameswararao B, Kesavulu M M & Apparao C, Evaluation of antidiabetic effect of Momordica cymbalaria fruit in alloxan-diabetic rats, Fitoterapia, 74 (2003) 7.
43. Kehlenbrink S, Koppaka S, Martin M, Relwani R, Cui M H, Hwang J H, Li Y, Basu R, Hawkins M & Kishore P, Elevated NEFA levels impair glucose effectiveness by increasing net hepatic glycogenolysis, Diabetologia, 55 (2012) 3021.
44. Abumrad N A, Forest C C, Regen D M & Sanders S, Increase in membrane uptake of long-chain fatty acids early during preadipocyte differentiation, Proc Natl Acad Sci U S A, 88 (1991) 6008.
45. Petersen K F, Laurent D, Rothman D L, Cline G W & Shulman G I, Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans, J Clin Invest, 101 (1998) 1203.